Literature DB >> 15284123

Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.

Alexey Ushmorov1, Olga Ritz, Michael Hummel, Frank Leithäuser, Peter Möller, Harald Stein, Thomas Wirth.   

Abstract

Immunoglobulin production is impaired in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL) in spite of functional clonal rearrangements. The presence of "crippling" mutations in coding and regulatory regions, as well as down-regulation of B-cell-specific transcription factors, has been suggested as a potential reason for the lack of immunoglobulin (Ig) chain gene transcription. We have investigated the impact of epigenetic silencing in suppressing Ig heavy (H)-chain expression. Chromatin immunoprecipitation (ChIP) was used to analyze transcription factor binding to octamer motifs present in the IgH regulatory regions. Transcription factors were bound to these motifs in control cell lines, however, they were absent in the cHL-derived cell lines KMH2, L1236, and L428. Ectopic expression of octamer-binding transcription factor (Oct2) and/or B-cell Oct binding protein/Oct-binding factor (BOB.1/OBF.1) did not result in any measurable binding to these sites. Increased histone 3 Lysine 9 (H3-K9) methylation was observed in the promoter region of the IgH locus in L428 and L1236 cells. This is a typical feature of heterochromatic, transcriptionally silent regions. Treatment of cHL-derived cell lines with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) partially reactivated IgH transcription and affected chromatin modifications. Our results suggest an important role of epigenetic silencing in the inhibition of IgH transcription in HRS cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15284123     DOI: 10.1182/blood-2003-04-1197

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress.

Authors:  Jinsuk Kang; Matthew Gemberling; Mitsuhiro Nakamura; Frank G Whitby; Hiroshi Handa; William G Fairbrother; Dean Tantin
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

3.  Mediastinal gray zone lymphoma.

Authors:  Leticia Quintanilla-Martinez; Falko Fend
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

Review 4.  Molecular pathogenesis of Hodgkin lymphoma.

Authors:  Momoko Nishikori; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 5.  Is Hodgkin lymphoma just another B-cell lymphoma?

Authors:  Harald Stein; Roshanak Bob
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

6.  DNA methylation patterns in EBV-positive and EBV-negative Hodgkin lymphomas.

Authors:  Myriam Ben Dhiab; Sonia Ziadi; Sarra Mestiri; Riadh Ben Gacem; Feryel Ksiaa; Mounir Trimeche
Journal:  Cell Oncol (Dordr)       Date:  2015-09-08       Impact factor: 6.730

7.  Circulating clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Richard J Jones; Christopher D Gocke; Yvette L Kasamon; Carole B Miller; Brandy Perkins; James P Barber; Milada S Vala; Jonathan M Gerber; Lan L Gellert; Mark Siedner; M Victor Lemas; Sarah Brennan; Richard F Ambinder; William Matsui
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

8.  Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.

Authors:  Askar Akimzhanov; Laszlo Krenacs; Timm Schlegel; Stefan Klein-Hessling; Enikö Bagdi; Eva Stelkovics; Eisaku Kondo; Sergei Chuvpilo; Philipp Wilke; Andris Avots; Stefan Gattenlöhner; Hans-Konrad Müller-Hermelink; Alois Palmetshofer; Edgar Serfling
Journal:  Am J Pathol       Date:  2007-12-21       Impact factor: 4.307

9.  IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis.

Authors:  Ferenc A Scheeren; Sean A Diehl; Laura A Smit; Tim Beaumont; Marianne Naspetti; Richard J Bende; Bianca Blom; Kennosuke Karube; Koichi Ohshima; Carel J M van Noesel; Hergen Spits
Journal:  Blood       Date:  2008-02-22       Impact factor: 22.113

10.  Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).

Authors:  Derek Murphy; Jeremy Parker; Minglong Zhou; Faisal M Fadlelmola; Christian Steidl; Aly Karsan; Randy D Gascoyne; Hong Chen; Diponkar Banerjee
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.